KÖZLEMÉNYJEGYZÉK (Szabó Attila)

KÖZLEMÉNYJEGYZÉK (Szabó Attila) A PhD értekezést követően megjelent közlemények A disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, Heemann U. Effect of angiotensinconverting enzyme inhibition on growth factor mrna in chronic renal allograft rejection in the rat. Kidney Int 2000, 57; 982-991 IF: 4,371 Független idézettség: 48 Szabo A, Tulassay T, Melegh B, Szabo T, Vannay A, Fekete A, Süveges Zs, Reusz GS. Hyperhomocysteinemia and MTHFR C677T gene polymorphism in renal transplant patients. Arch Dis Child 2001; 85: 47-49 IF:2,129 Független idézettség: 8 3. Viklicky O, Hubacek JA, Vitko S, Heemann UW, Vasarhelyi B, Lacha J, Kohnle M, Szabo A. G- protein β3-subunit and enos gene polymorphism and long-term renal graft function. Kidney Blood Press R 2002; 25(4): 245-249I IF: 0.968 Független idézettség: 2 Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. Kidney Int 2002; 62 (4): 1364-1371 IF: 5,016 Független idézettség: 11 5. Szabó Attila, Müller Veronika. A transzplantált vese hosszú távú működését befolyásoló faktorok. Orvosi Hetilap 2002, 143(51): 2811-2819 Független idézettség: 2 6. Szabo AJ, L Wagner A Erdely K, Lau C, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003, 64(5): 1765-1771 IF: 5,302 Független idézettség: 1 7. Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo AJ. Sex differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. J Physiol (London.) 2004; 555(2): 471-80 IF: 4,346 Független idézettség: 9 8. Müller V, Szabó A. Nemi különbségek a vesebetegségek progressziójában. Lege Artis Medicinae 2004; 14(1): 26-31 Független idézettség: 1 9. Vannay A, Fekete A, Müller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo AJ. The effects of histamine and the H2 receptor antagonist ranitidine on ischemia induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. Kidney Blood Press R 2004; 27: 105-113 IF: 1,067 Független idézettség: 2 10. Fekete A, Viklicky O, Hubácek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between Heat Shock Protein (HSP) 70s and Toll like Receptor Polymorphisms with Long-Term Renal Allograft Survival. Transplant Int 2006; 19: 190 196 IF: 1,797

1 Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock protein 72 expression and localization in rats following renal ischaemia-reperfusion injury. Am J Physiol Renal Physiol. 2006; 291(4): F806-F811 IF: 4,263 Független idézettség: 1 Össz IF: 29,259 Független idézettség: 85 A disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények 1 Heemann U, Szabo A, Hamar P, Müller V, Witzke O, Philipp Th. LPS pretreatment protects from renal ischemia/reperfusion injury. Possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156: 287-293 IF: 6,971 Független idézettség: 31 13. Viklicky O, Zou H, Müller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502 IF: 4,035 Független idézettség: 37 1 Hamar P, Liu S, Viklicky O, Szabo A, Müller V, Heemann U. Cyclosporine A and Azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69: 1290-1295 IF: 4,035 Független idézettség: 3 15. Losonczy G, Kriston T, Szabo A, Müller V, Harvey J, Hamar P, Heemann U, Baylis C. Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res 2000; 47: 183-191 IF: 3,783 Független idézettség: 18 16. Reusz GS Szabo A, Ferenc P, Kenesei É, Sallay P, Latta K, Szabó A, Szabó A. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000; 83: 146-151 IF: 1,866 Független idézettség: 19 17. Müller Veronika, Szabó Attila, Becker Gerold, Delfs Michael, Veres Tibor, Albrecht Karl-Heinz, Philipp Thomas, Heemann Uwe. Húgyúti fertőzések hatása a transzplantált vese chronicus kilökődésére. Hypertonia és Nephrologia 2000; 4(3): 141-145 18. Viklicky O, Muller V, Zou H, Szabo A, Vitko S, Heemann U. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. Transplant P 2001; 33(3): 2320-2321 IF:0,568 Független idézettség: 2 19. Hamar P, Szabo A, Muller V, Heemann U. The involvement of activated T-cells and growth-factor production in the early and late phase of chronic kidney allograft nephropathy in rats. Transpl Int 2002; 15(9-10): 446-454 IF: 2,520 Független idézettség: 5 20. Losonczy Gy,, Kriston T, Szabó A, Müller V, Harvey J, Heemann U, Baylis C. Nemi különbségek a kísérletes endotoxin sokk kialakulásában. A nitrogén-monoxid szintézis jelentősége. Medicina Thoracalis 2002; 55: 66-73 2 Erdely A, Wagner L, Müller V, Szabo A, Baylis C. Protection of Wistar Furth rat from renal disease is associated with maintained renal nitric oxide. J Am Soc Nephrol 2003; 14(10):2526-33 IF: 7,499 Független idézettség: 7 2 Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, Viklicky O. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: Effect of tacrolimus. Transplant P 2005; 37(1): 352-354 IF: 0,799 Független idézettség: 1

23. Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of Long-Term Protective Effect of Antioxidant/Anti-Inflammatory Therapy in Transplant-Induced Ischemia/Reperfusion Injury. Am J Nephrol. 2006; 26(3): 213-217 IF: 2,459 2 Reusz György, Szabó Attila, Remport Ádám, Szabó József, Járay Jenő. Veseátültetés gyermekkorban. Gyermekgyógyászati szemle 2006; 11(3-4): 99-108 Össz impakt faktor: 34,535 Független idézettség: 123 Nem a disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények 25. Molnar Z, Farkas V, Nemes L, Reusz GS, Szabo AJ. Hyponatraemic seizures resulting from inadequate post-operative fluid intake following a single dose of desmopressin. Nephrol Dial Transpl 2005; 20: 2265-2267 IF: 2,976 Független idézettség: 1 Össz impakt faktor: 2,840 Független idézettség: 1 Nem a disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények 26. Miltényi G, Tory K, Stubnya G, Sallay P, Dobos M, Vásárhelyi B, Szabo A, Reusz G. Monitoring cardiovascular changes during hemodialysis in children. Pediatr Nephrol 2001; 16: 19-2 IF:1,391 Független idézettség: 1 27. Tory K, Tóth-Heyn P, Szabo A, Stubnya G, Reusz GS. Signs of autonomic neuropathy in childhood uremia. Pediatr Nephrol 2001; 16: 25-28 IF: 1,391 Független idézettség: 3 28. Hamar P, Peti-Peterdi J, Szabo A, Becker G, Flach R, Rosivall L, Heemann U. Interleukin-2-dependent mechanism are involved in the development of glomerulosclerosis after partial renal ablation in rats. Exp Nephrol 2001; 9(2): 133-141 IF:1,881 Független idézettség: 5 29. Tory K, Horváth E, Süveges Z, Fekete A, Sallay P, Berta K, Szabó T, Szabo AJ, Tulassay T, Reusz GS. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a doubleblind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol 2004; 61(5): 316-323 IF: 1,316 30. Reusz György, Szabó Attila, Fekete Andrea. Idiopathiás nephrosis szindróma gyermekkorban. Orvosi Hetilap 2006; 147(47): 2251-2260 3 Karoly E, Fekete A, Banki NF, Szebeni B, Vannay A, Szabo AJ, Tulassay T, Reusz GS. Heat Shock Protein 72 (HSPA1B) Gene Polymorphism and Toll-Like Receptor (TRL) 4 Mutation are Associated with Increased Risk of Urinary Tract Infection in Children. Ped Res 2007 (közlésre elfogadva) IF: 2,875 Össz impakt faktor: 8,854 Független idézettség: 9

A PhD értekezést megelőzően megjelent közlemények A disszertáció témájában a PhD értekezést megelőzően megjelent első- vagy utolsószerzős közlemények 3 Szabo A, Viazov S, Heemann U., Kribben A., Philipp Th., Roggendorf M. GBV-C/HGV infection in renal dialysis and transplant patients. Nephrol Dial Transpl 1997; 12: 2380-2384 IF: 1,682 Független idézettség: 17 33. Szabo A, Sallay P, Kribben A, Ross S, Philipp Th, Roggendorf M., Tulassay T., Heemann U. Hepatitis G virus infection in children on dialysis and after renal transplantation. Pediatr Nephrol 1998; 12: 93-95 IF: 1,158 Független idézettség: 3 3 Szabo A, Heemann U. Ischemia/reperfusion and chronic allograft rejection. Transplant P 1998; 30: 4281-4284 IF: 0,740 Független idézettség: 22 35. Szabo A, Patschan O, Kuttler B., Müller V., Philipp Th, Rettig R., Heemann U. Hypertension accelerates the pace of chronic allograft rejection in rat. Transplant Int 1998; S11: 10-14 IF: 1,870 Független idézettség: 6 36. Szabó A, Heemann U, Müller V, Reusz Gy, Sallay P, Viazov S, Tulassay T. Hepatitis G vírus infekció vesetranszplantált és dializált gyermek és felnőtt betegekben. Orvosi Hetilap 1999; 140(29): 1619-1623 Független idézettség: 4 37. Szabó A, Müller V, Patschan O, Kuttler B, Rettig R, Reusz G, Heemann U. Hypertónia hatása a transzplantált vese krónikus kilökődésére. Hypertonia és Nephrologia 1999; 3(3): 127-131 Össz impakt faktor: 5,450 Független idézettség: 52 A disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények 38. Müller V, Hamar P, Szabo A, Knust E, Vogelsang M, Heemann U. Effect of mycophenolate mofetil on the in-vivo infiltration of lymphocytes in the rat remnant kidney. Transplant P 1998, 30: 982 IF: 0,740 Független idézettség: 11 39. Witzke O, Becker G, Erhard J, Lütkes P, Szabo A, Philipp Th, Heemann U. Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation. Clin Nephrol 1998, 49: 24-27 IF: 1,323 Független idézettség: 3 40. Müller V, Hamar P, Vogelsang M, Szabó A, Philipp T, Heemann U. In-vivo migration of lymphocytes in chronically rejecting rat kidney allografts: essential role of CD18. Transplant Int 1999; 12: 145-151 IF: 1,599 Független idézettség: 2 4 Müller V, Szabó A, Viklicky O, Portl S, Heemann U. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011-2020 IF: 3,807 Független idézettség: 27 4 Hamar P, Szabó A, Kovács G, Kökény G, Heemann U, Rosiwall L. Az interleukin-2 által közvetített mechanizmusok szerepet játszanak transplantált patkányvese chronicus kilökődésében. Hypertonia és Nephrologia 1999; 3(2): 102-109

43. Hamar P, Szabo A, Muller V, Heemann U. Involvement of interleukin-2 and growth factors in chronic kidney allograft rejection in rats. Transplant P 2001; 33: 2160-2162 IF: 0,568 Független idézettség: 1 Össz impakt faktor: 8,037 Független idézettség: 44 Nem a disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények 4 Ross RS, Viazov S, Schmitt U, Schmolke S, Tacke M, Ofenloch-Haehnle B, Holtman M, Müller N, Da Villa G, Yoshida CF, Oliveira JM, Szabo A, Paladi N, Kruppebacher JP, Philipp Th, Roggendorf M. Distinct prevalence of antibodies to the E2 protein of GB virus C/hepatitis G virus in different parts of the world. J Med Virol 1998; 54: 103-106 IF: 2,594 Független idézettség: 36 45. Reusz György, Sallay Péter, Dobos Mariann, Szabó András, Szabó Attila, Szabó Antal, Tulassay Tivadar. Az oxalátürítés és a vizelet kalcium-oxalát telítettsége izolált haematuriában valamint idiopathiás hypercalciuriában. Gyermekgyógyászat 1998; 6: 560-567 46. Szabó A, Kenesei É, Szabó A, Arató A, Reusz Gy, Tulassay T. Bone turnover index in children and their changes in renal diseases. Klin Kisérl Lab Med = Clin Exp Lab Med 2000; 27: 66-71 (angol nyelvű) Össz impakt faktor: 2,594 Független idézettség: 36

Impakt faktor összesítés és százalékos arány a küszöbértékhez viszonyítva Az első- vagy utolsószerzős publikációk impakt faktora: 37,549 (75,098%) Az első- vagy utolsószerzős publikációk független idézettsége: 138 (69%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények impakt faktorának aránya: 32,099/5,450 (85,48%/14,52%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények független idézettségének aránya: 86/52 (62,3%/37,7%) A PhD Disszertációt követően és megelőzően publikált összes közlemény impakt faktorának aránya: 75,488/16,081 (82,44%/17,56%) Összes impakt faktor: 91,569 Független idézettség: 350 Összes idézettség: 422

Könyvfejezetek: Szabó Attila: Hypertonia és érrendszer. In: Reusz György, Tulassay Tivadar, Fekete Farkas Pál. (szerk.): Hypertonia a gyermekkorban. Golden Book Kiadó, Budapest, 2002 Szabó Attila: Tubuláris megbetegedések. XXXII fejezet 1727-174 In: Oláh Éva (szerk.): Gyermekgyógyászati kézikönyv. Medicina Könyvkiadó Rt., Budapest, 2004 3. Szabó Attila: Befolyásolják-e a nem és a nemi hormonok az átültetett vese működését? 48-50. In: Karátson Dávid, Tordai Attila, Nagy Mariann (szerk.): A Magyary Zoltán Posztdoktori Ösztöndíj. Gondolat Kiadó, Budapest, 2004 Tóth-Heyn Péter, Szabó Attila: A gyermekkori vesebetegségek farmakológiája. 13. fejezet 305-336. In: Fekete Ferenc, Gyurkovits Kálmán (szerk.): Gyermekgyógyászati farmakoterápia. B+V Lap- és Könyvkiadó Kft. 2006 Folyóiratban megjelent idézhető előadás absztraktok: Heemann U, Szabó A, Schleimer K, Müller V, Philipp T. Enalapril verlangsamt die chronische Abstossung im Rattenmodell. Nieren Hochdruck 1997, 26: 493 Heemann U, Hamar P, Szabó A, Müller V, Witzke O, Schade U, Philipp Th. IL-2 dependent mechanisms are involved in chronic kidney allograft rejection in rats. J Am Soc Nephrol 1997, 8: 657 3. Lütkes P, Witzke O, Erhard J, Szabó A, Philipp Th, Heemann UW. Long-term tacrolimus rescue therapy is useful in kidney transplant recipients remaining on dialysis after steroid resistant acute rejection. Nephrol Dial Transplant 1997, 12: 203 Müller V, Hamar P, Szabó A, Vogelsang M, Philipp Th, Heemann U. In-vivo migration of lymphocytes in rejecting rat kidney allografts: essential role of CD18. Nephrol Dial Transpl 1997, 12: 197 5. Rubbert-Lauterbach F, Szabó A, Boehm W, Feldhoff C, Roggendorf M, Sallay P, Bonzel KE, Ballauff A. Vorkommen von Hepatitis-G-Virus (HGV) bei Kindern mit regelmässiger Hämo- und Peritonealdyalisebehandlungen und nach Nierentransplantation. Monatsschr Kinderheilk 1997, 145: 555 6. Rubbert-Lauterbach F, Szabó A, Boehm W, Feldhoff C, Roggendorf M, Sallay P, Ballauff A, Bonzel KE. Prevalence of hepatitis G-virus in children on regular dialysis (HD and PD) treatment and after renal transplantation (TP). Pediatr Nephrol 1997, 11: 75 7. Szabó A, Rubbert-Lauterbach F, Boehm W, Roggendorf M, Sallay P, Ballauff A, Bonzel KE. Vorkommen von Hepatitis-G-Virus (HGV) bei Kindern mit regelmässiger Hämo- und Peritonealdialysebehandlung. Monatsschr Kinderheilk 1997, 145: 215 8. Szabó A, Sallay P, Kribben A, Müller V, Roggendorf M, Tulassay T, Heemann U. Hepatitis G virus infection in children on dialysis and after renal transplantation. Nephrol Dial Transplant, 1997, 12: 114 9. Toronyi É, Járay J, Remport A, Gáti Z, Szabó A, Heemann U. Incidence of hepatitis G virus in kidney transplanted patients. Nephrol Dial Transplant 1997, 9: 229 10. Hamar P, Viklicky O, Szabó A, Müller V, Rosivall L, Heemann U. Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. J Am Soc Nephrol 1998, 9: 651A 1 Hamar P, Peti_peterdi J, Szabó A, Rosivall L, Heemann U. IL-2 dependent mechanisms in the development of glomerulosclerosis after ¾ renal ablation in rats. J Am Soc Nephrol 1998, 9: 89A 1 Heemann U, Szabó A, Müller V, Hamar P, Kribben A, Philipp Th. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection in the rat. J Am Soc Nephrol 1998, 9: 678A

13. Heemann U, Müller V, Szabó A, Viklicky O, Portl S, Kribben A, Philipp Th. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. J Am Soc Nephrol 1998, 9: 678A 1 Müller V, Szabó A, Vikliczky O, Zou H, Heemann U. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. Nephrol Dial Transplant 1998, 13: A251 15. Szabó A, Kribben A, Sallay P, Roggendorf M, Philipp Th, Tulassay T, Heemann U. Hepatitis G virus infection in adults and children treated with hemo- or peritoneal dialysis. Periton Dialysis Int 1998, 18: 107 16. Szabó A, Schleimer K, Müller V, Hamar P, Viklicky O, Heemann U. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection. Nephrol Dial Transplant 1998, 13: 251A 17. Szabó A, Schleimer K, Müller V, Hamar P, Reusz G, Viklicky O, Heemann U. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection. Pediatr Nephrol 1998, 12: C98 18. Szabó A, Müller V, Schleimer K, Hamar P, Viklicky O, Heemann U. Enalapril reduces growth factor production in chronic renal allograft rejection in the rat. Pediatr Transplant 1998, 2(Suppl. 1): 81 19. Viklicky O, Zou H, Müller V, Szabó A, Heemann U. SDZ RAD prevents early manifestation of chronic rejection in rat renal allografts. Nephrol Dial Transplant 1998, 13: A255 20. Zou H, Viklicky O, Kohnle M, Müller V, Szabó A, Lutz J, Heemann U. SDZ-RAD verhindert frühe Manifestationen einer chronischen Rejektion beim Nierenallotransplant Modell der Ratte. Z Transplantationsmedizin 1998, Suppl.: 92 2Heemann U, Viklicky O, Zou H, Müller V, Szabó A, Lacha J. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. J Am Soc Nephrol 1999, 10: 703A-704A 2 Reusz G, Szabó A, Szabó A, Szabó A, Sallay P. Characterization of bone metabolism in chronic pediatric renal diseases. J Am Soc Nephrol 1999, 10: 603A 23. Szabó A, Kenesei É, Arató A, Reusz G, Szabó A. Bone turnover index in children and their changes in renal diseases. Clin Chem Lab Med 1999, 37(Suppl.): S436 2 Szabó A, Müller V, Hamar P, Vogelsang M, Tulassay T, Heemann U. Die in-vivo Migration von Lymphozyten in Nieren die chronisch abgestossen werden, wird hauptsächlich durch CD18 vermittelt. Monatsschr Kinderh 1999, 147: 229 25. Szabó A, Patschan O, Müller V, Reusz G, Rettig R, Heemann U. The role of hypertension in chronic renal allograft dysfunkction. Pediatr Nephrol 1999, 13: C86 26. Reusz G, Szabó A, Kenesei É, Sallay P, Tóth-Heyn P, Thole H, Szabó A, Arató A, Péter F. Bone metabolism and mineral density in transplanted patients. Pediatr Nephrol 2000, 14: C106 27. Reusz G, Szabó A, Sallay P, Szabó A, Kenesei É, Tulassay T. Charakterisierung des Knochenmetabolismus in chronischen Nierenerkrankungen. Monatsschr Kinderh 2000, 148: 195 28. Szabó A, Müller V, Schleimer K, Reusz G, Vogelsang M, Heemann U. Enalapril hemmt die Produktion von Wachstumsfaktoren in der chronischen Abstossung. Monatsschr Kinderh 2000, 148: 207 29. Szabó A, Müller V, Viklicky O, Reusz G, Tulassay T, Heemann U. The influence of sex hormones and gender related differences on chronic renal allograft rejection. Pediatr Nephrol 2000, 14: C109 30. Szabo AJ, Tulassay T, Melegh B, Szabo A, Szabo T, Sallay P, Müller V, Reusz GS. Hyperhomozysteinämie und MTHFR-C677T-Genpolymorphismus bei nierentransplantierten Jugendlichen. Nieren und Hochdruckkr 2001, 30/3: 121 3 Fekete A, Müller V, Vannay A, Kocsis I, Heninger E, Vér A, Tulassay T, Szabó AJ. Gender differences during ischemia/reperfusion injury in rat kidney: the role of HSP72 and Na+/K+. Monatsschr Kinderh 2001, 149(Suppl. ): S11

3 Fekete A, Melegh B, Szabó T, Müller V, Tulassay T, Reusz GS, Szabó AJ. Hyperhomocysteinemia and polymorphism of the MTHFR gene in renal transplant children. Monatsschr Kinderh 2001, 149 (Suppl. ): S17 33. Wagner L, Erdely A, Szabó A, Baylis C. Decreased renal nitric oxide synthase (NOS) activity occurs early in chronic progressive renal disease (CRD). J Am Soc Nephrol 2001, 12: A4335 3 Fekete A, Vannay A, Vér A, Vásárhelyi B, Müller V, Reusz G, Tulassay T, Szabó AJ. Gender differences in renal Na/K ATPase in rats. Pediatr Nephrol 2002, 17: C62 35. Erdely A, Szabo A, Wagner L, Baylis C. Decreased neuronal (n) nitric oxide synthase (NOS) and progressive chronic renal disease (CRD). J Am Soc Nephrol 2002, 13: 344A 36. Fekete A, Vannay A, Vér A, Vásárhelyi B, Müller V, Reusz G, Tulassay T, Szabó AJ. Gender differences in renal Na+/K+ ATPase (NKA) during ischemia/reperfusion injury in rats. J Am Soc Nephrol 2002, 13: 755A 37. Müller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabó AJ. Sexual dimorphism in renal ischemia-reperfusion injury on rats: possible role of endothelin. J Am Soc Nephrol 2002, 13: 756A 38. Müller V, Szabo A, Baylis C. Changes in renal endothelial and neuronal nitric oxide synthase (enos, nnos) protein abundance in chronic allograft rejection in rats. J Am Soc Nephrol 2002, 13: 558A 39. Szabo A, Müller V, Baylis C. Gender difference in endothelial and neuronal nitric oxide synthase (enos and nnos) expression in kidney cortex following low dose Cyclosporine-A (CsA) treatment. J Am Soc Nephrol 2002, 13: 372A 40. Szabo A, Erdely A, Müller V, Baylis C. Strain differences in renal neuronal nitric oxide synthase (nnos) protein abundance. J Am Soc Nephrol 2002, 13: 737A 4 Szabo A, Müller V, Erdely A, Baylis C. Gender based immunosuppression? Different effects of cyclosporine A (CsA) and rapamycin (Rapa) on renal endothelial and neuronal nitric oxide synthase (enos and nnos) expression. Nephrol Dial Transplant 2003, 18 (Suppl. ): 792 4 Müller V, Losonczy G, Heemann U, Fekete A, Vannay A, Reusz G, Tulassay T, Szabo A. The effect of gender and sexual steroids on renal ischemia-reperfusion injury. Nephrol Dial Transplant 2003, 18 (Suppl. ): 604 43. Tory K, Suveges Zs, Sallay P, Berta K, Szabo A, Tulassay T, Reusz G. A new parameter designed to differentiate the effect of autonomic neuropathy from that of sympathetic overactivity on heart rate variability in hemodialysis patients. Nephrol Dial Transplant 2003, 18 (Suppl. ): 535 4 Szabo AJ, Müller V, Erdely A, Baylis C. Gender based immunosuppression? Pediatr Nephrol 2003, 18: C21 45. Szabó A, Fekete A, Vannay Á, Losonczy Gy, Heemann U, Reusz Gy, Müller V. Nemi különbségek a hemodinamikában a vese ischémia/reperfúziós károsodását követően. Hypertonia és Nephrologia 2003, 7 (S4): 136 46. Fekete A, Viklicky O, Treszl A, Körmendy R, Heemann U, Teplan V, Reusz Gy, Tulassay T, Szabó AJ. Összefüggés a HSP70 és a TOLL-like receptor genetikai polimorfizmusai, valamint a graftok hosszú távú túlélése között vesetranszplantált betegcsoportokban. Hypertonia és Nephrologia 2003, 7 (3-4): 212 47. Kökény G, Regős A, Antus B, Szabó A, Rosival L, Hamar P. A donor vese perfúziója alapvetően meghatározza a korai graftfunkciót vesetranszplantált patkányban. Hypertonia és Nephrologia 2003, 7 (3-4): 215 48. Müller V. Baylis C, Szabó A. Renalis endothelialis és neuronális nitrogén-monoxid-szintáz (enos és nnos) fehérje expresszió krónikus allograft-nephropathiás nőstény patkányokban. Hypertonia és Nephrologia 2003, 7 (3-4): 218

49. Szabó A, Müller V, Erdely A, Baylis C. A kísérletes vesetranszplantációban használt állatmodell nitrogenmonoxid (NO) függő? Hypertonia és Nephrologia 2003, 7 (3-4): 220 50. A Fekete, A Vannay, A Vér, B Vasarhelyi, V Müller, G Reusz, T Tulassay, AJ Szabo. Geschlechtsspezifische Veränderungen der Na+-K+-ATPase nach Ischämie/Reperfusionsschädigung der Rattenniere. Nieren- und Hochdruckkrankheiten 2004, 33/3: 146 5 Szabó A, Molnár Z. Akut vízmérgezés dezmopresszin kezelés után. Medicina Thoracalis 2004-Suppl., 36 5 Müller V, Szabó A, Rusai K, Losonczy Gy, Muraközy G, Magyar P. HSP70 és TLR-4 polimorfizmus vizsgálata krónikus obstruktív tüdőbetegekben. Medicina Thoracalis 2004-Suppl., 49 53. Bloudicková S, Rajnoch J, Skaroupková P, Szabo A, Muller V, Vikliczky O. Role nnos a pohlavi v ischemicko-reperfuznim poskozeni: klinická a morfologická analyza. Aktuality V Nefrologii 2004-Suppl, 28-29 5 AJ Szabo, V Müller, A Erdely, GS Reusz, C Baylis. Neuronal nitric oxide synthase (nnos) in chronic allograft nephropathy: Role of immunosuppressions and gender. Ped Nephrol 2004, 19: C132 55. A Fekete, A Vannay, A Ver, B Vasarhelyi, V Müller, N Ouyang, G Reusz, T Tulassay, AJ Szabo. Gender differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. Ped Nephrol 2004, 19: C77 56. A Szabo, A Fekete, G Reusz, K Rusai, J Rajnoch, V Müller, O Viklicky. Die Rolle des nnos nach ischämischer/reperfusorischer Beschädigung der Nieren: Geschlechtsunterschiede. Nieren- und Hochdruckkrankheiten 2005, 34/4: 182 57. A Szabo, A Vannay, V Muller, A Ver, K Rusai, G Reusz, A Fekete. Gender differences in the ischemia induced acute renal failure: the role of Na/K ATPase and HSP7 Ped Nephrol 2005, 20(9): C26 58. K Rusai, A Fekete, O Viklicky, V Müller, B Szebeni, G Reusz, T Tulassay, A Szabo. The role of neuronal nitric oxyde synthase (nnos) inhibition in renal ischemia-reperfusion (IR) injury: gender differences. Ped Nephrol 2005, 20(9): C110 59. Fekete A, Banki F Viklicky O, Hubacek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Pediatr Nephrol 2006, 21(10): C76 60. Bánki Nóra, Fekete Andrea, Andrej Viklicky, Uwe Heemann, Müller Veronika, Reusz György, Szabó Attila. HSP70 és a Toll-like receptor 4 polimorfizmusai és a vesetranszplantátum hosszútávú túlélése. Hypertonia és Nephrologia 2006, 10: 12 6 Fekete Andrea, Szabó Attila. Nemi különbségek a renalis ischemia/reperfuziós károsodásban Hypertonia és Nephrologia 2006, 10: 12 6 Szabó Attila, Fekete Andrea. Nemi különbségek a renalis ischemia/reperfuziós károsodásban Hypertonia és Nephrologia 2006, 10: 12

HIVATKOZÁSI JEGYZÉK (Szabó Attila) A PhD értekezést követően megjelent közlemények A disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények 47. Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, Heemann U. Effect of angiotensinconverting enzyme inhibition on growth factor mrna in chronic renal allograft rejection in the rat. Kidney Int 2000, 57; 982-991 IF: 4,371 Független idézettség: 48 Eddy A A. Molecular basis of renal fibrosis. PEDIAT NEPHROL, 15: 290-301 (2000) Gilbert R E, Kelly D J, Cox A J, Wilkinson Berka J L, Rumble J R, Osicka T, Panagiotopoulos S, Lee V, Hendrich E C, Jerums G, Cooper M E. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. DIABETOLOGIA, 43: 1360-1367 (2000) Vazquez M A, Jeyarajah D R, Kielar M L, Lu C Y. Long-term outcomes of renal transplantation: a result of the original 3. endowment of the donor kidney and the inflammatory response to both alloantigens and injury. CURR OPIN NEPHROL HYPERTENS, 9: 643-648 (2000) Abdi R, Huong T T B, Zee R, Brenner B M, Milford E L. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. TRANSPLANTATION, 72: 726-729 (2001) Antus B, Exton M S, Rosivall L. Angiotensin II: A regulator of inflammation during renal disease? INT J * 5. IMMUNOPATHOL PHARMACOL, 14: 25-30 (2001) 6. Danovitch G M. Can ACE inhibitors prevent chronic allograft failure? AMER J KIDNEY DIS, 37: 866-869 (2001) Danovitch G M. Reduction of cardiovascular morbidity in kidney transplant recipients. CURRENT OPINION IN 7. ORGAN TRANSPLANTATION, 6: (2) 145-150 (2001) Fellstrom B. Nonimmune risk factors for chronic renal allograft disfunction. TRANSPLANTATION, 71: SS10-SS16 8. (2001) Gilbert R E, Wilkinson Berka J L, Kelly D J. Angiotensin and renal fibrosis. CONTRIB NEPHROL, (135):171-86 9. (2001) Heemann U, Philipp T. Can ACE inhibitors prevent chronic allograft failure? Reply. AMER J KIDNEY DIS, 37: 869- * 10. 870 (2001) Olyaei A J, De Mattos A M, Bennett W M. Nephrotoxicity of immunosuppressive drugs: New insight and preventive 1 strategies. CURRENT OPINION IN CRITICAL CARE, 7: (6) 384-389 (2001) Paskalev E. Chronic failure of renal transplant and ace inhibitors. NEPHROLOGY, DIALYSIS AND 1 TRANSPLANTATION, 7: 34-37 (2001) Shibab F S. Renin-angiotensin system in chronic renal allograft dysfunction. CONTRIB NEPHROL, (135):222-34 13. (2001) Smit van Oosten A, Navis G, Stegeman C A, Joles J A, Klok P A, Kuipers F, Tiebosch A T M G, van Goor H. Chronic 1 blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J PATHOL, 194: 122-129 (2001) Womer K L, Lee R S, Madsen J C, Sayegh M H. Tolerance and chronic rejection. PHIL TRANS ROY SOC LONDON B, 15. 356: 727-738 (2001) Di Paolo S, Schena A, Stallone G, Grandaliano G, Soccio M, Cerullo G, Gesualdo L, Schena F P. Captopril enhances transforming growth factor (TGF)-beta(1) expression in peripheral blood mononuclear cells: A mechanism 16. independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. TRANSPLANTATION, 74: 1710-1715 (2002) 17. Fellstrom B. Chronic renal allograft dysfunction. TransplantLinc, 4: (1) 77-83 (2002) Fischereder M, Kruger B, Kramer B K. Chemokine and renal transplantation [Chemokine und nierentransplantation]. 18. TRANSPLANTLINC, 4: (1) 47-57 (2002) Gourishankar S, Melk A, Halloran P. Nonimmune mechanisms of injury in renal transplantation. TRANSPLANTATION 19. REVIEWS, 16: (2) 73-86 (2002) Jugdutt B I, Menon V, Kumar D, Idikio H. Vascular remodeling during healing after myocardial infarction in the dog 20. model - Effects of reperfusion, amlodipine and enalapril. J AMER COLL CARDIOL, 39: 1538-1545 (2002) Lin J, Valeri A M, Markowitz G S, D Agati V D, Cohen D J, Radhakrishnan J. Angiotensin converting enzyme 2 inhibition in chronic allograft nephropathy. TRANSPLANTATION, 73: 783-788 (2002) Richter M H C, Richter H, Barten M, Schramm D, Gummert J, Mohr F W, Skupin M, Olbrich H G. Angiotensin II type 2 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study. TRANSPLANT PROC, 34: 1484-1485 (2002)

Sola R, Paredes D, Antonijoan R M, Estorch M, Vila L P, Guirado L L, Diaz J M, Gich I, Barbanoj M J. Glomerular 23. hyperfiltration, intrarenal hemodynamics, and chronic allograft nephropathy: Physiopathology of chronic allograft nephropathy. TRANSPLANT PROC, 34: 340-+ (2002) Song E W, Zou H Q, Yao Y S, Proudfoot A, Antus B, Liu S Y, Jens L, Heemann U. Early application of Met-RANTES * 2 ameliorates chronic allograft nephropathy. KIDNEY INT, 61: 676-685 (2002) Takahara S, Moriyama T, Kokado Y, Hanafusa T, Yazawa K, Yi S, Tanaka T, Kojima Y, Tabata T, Oka K, Imai E. 25. Randomized prospective study of effects of benazepril in renal transplantation: An analysis of safety and efficacy. Clinical and Experimental Nephrology, 6: (4) 242-247 (2002) Aldamiz Echevarria L, Sanjurjo P, Vallo A, Aguirre M, Perez Nanclares G, Gimeno P, Rueda M, Ruiz J I, Rodriguez 26. Soriano J. Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants. PEDIAT NEPHROL, 18: 749-755 (2003) Cantarovich F, Rangoonwala B. Therapeutic effects of angiotensin II inhibition or blockade on the progression of 27. chronic renal disease. INT J CLIN PRACT, 57: 801-822 (2003) Fellstrom B. Donor antigen-independent risk factors for chronic allograft nephropathy. TRANSPLANTATION 28. REVIEWS, 17: (2) 61-66 (2003) Gabriels G, August C, Grisk O, Steinmetz M, Kosch M, Rahn K H, Schlatter E. Impact of renal transplantation on small 29. vessel reactivity. TRANSPLANTATION, 75: 689-697 (2003) Ghods A J, Ossareh S. Beneficial effect of enalapril on slowing the progression of chronic renal allograft dysfunction. 30. TRANSPLANT PROC, 35: 2641-2642 (2003) Jeong H J, Kim Y S, Kwon K W, Kim M S, Kim S I, Choi K H, Lee H Y, Han D S, Park K. Segmental glomerulosclerosis 3 in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril. CLIN TRANSPLANT, 17: 108-113 (2003) Kamimura M, Orth S R. Altered tubular albumin degradation in the pathogenesis of albuminuria: additional 3 experimental evidence challenging the paradigm of glomerular capillary leakage. J HYPERTENSION, 21: 269-271 (2003) Lutz J, Zou H Q, Liu S Y, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with * 33. everolimus. TRANSPLANTATION, 76: 508-515 (2003) Orth S R, Odoni G, Karkoszka H, Ogata H, Viedt C, Amann K, Ferrari P, Ritz E. Combination treatment with an ETAreceptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant 3 vasculopathy in different aorta allotransplantation rat models. NEPHROL DIALYSIS TRANSPLANT, 18: 62-69 (2003) Powis S H. Halting chronic allograft nephropathy - Do we already have the drugs? NEPHRON CLIN PRACT, 95: 35. C73-C74 (2003) Richter M H C, Richter H R, Olbrich H G, Mohr F W. Two good reasons for an angiotensin-ii type 1 receptor blockade 36. with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. TRANSPLANT INT, 16: 26-32 (2003) Schindler R, Tullius S G, Tanriver Y, Noack K, Qun Y, Jurgensen J S, Frei U. Hypertension increases expression of 37. growth factors and MHC II in chronic allograft nephropathy. KIDNEY INT, 63: 2302-2308 (2003) Smit-van Oosten A, Stegeman C A, van Goor H. RAS blockade in experimental renal transplantation. Benefits and 38. limitations. Current Drug Targets - Cardiovascular and Haematological Disorders, 3: (1) 73-79 (2003) Tylicki L, Habicht A, Watschinger B, Horl W H. Treatment of hypertension in renal transplant recipients. CURR OPIN 39. UROL, 13: 91-98 (2003) Akcay A, Sezer S, Ozdemir F N, Arat Z, Atac F B, Verdi H, Colak T, Haberal M. Association of the genetic 40. polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. TRANSPLANTATION, 78: 892-898 (2004) Cheung C Y. Vascular endothelial growth factor activation of intramembranous absorption: A critical pathway for 4 amniotic fluid volume regulation. J SOC GYNECOL INVESTIGATION, 11: 63-74 (2004) Magee C C, Milford E. Clinical aspects of renal transplantation. In: Brenner B.M. (szerk.) Brenner and reactor's the 4 kidney, Philadelphia: Saunders, 200 2805-2848 Montanaro D, Gropuzzo M, Tulissi P, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani G L, Sainz M, Bresadola F, 43. Mioni G. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration. TRANSPLANT PROC, 36: 692-694 (2004) Muller V, Szabo A. Gender associated differences in the progression of renal diseases [Nemi kuu loo nbsegek a * 4 vesebetegsegek progressziojaban]. LEGE ARTIS MEDICINAE, 14: (1) 26-31 (2004) Namba Y, Moriyama T, Kyo M, Oka K, Kokado Y, Shi Y, Imamura R, Ichimaru N, Okuyama A, Takahara S. 45. Comparison of histopathological characteristics of allograft biopsy between responder and non-responder to antiproteinuric effect of angiotensin-converting enzyme inhibitor (ACEI). CLIN TRANSPLANT, 18: 29-33 (2004) Philipp S, Pagel I, Hohnel K, Lutz J, Buttgereit J, Langenickel T, Hamet P, Dietz R, Willenbrock R. Regulation of * 46. caspase 3 and Fas in pressure overload-induced left ventricular dysfunction. EUR J HEART FAIL, 6: 845-851 (2004) Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L, Schena F P. Sirolimus and angiotensinconverting enzyme inhibitors together induce tongue oedema in renal transplant recipients. NEPHROL DIALYSIS 47. TRANSPLANT, 19: 2906-2908 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft * 48. nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004)

Zaltzman J S, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with 49. biopsy-proven allograft nephropathy. NEPHROL DIALYSIS TRANSPLANT, 19: 940-944 (2004) Fellstrom B, Holdaas H, Jardine A G, Nyberg G, Gronhagen Riska C, Madsen S, Neumayer H H, Cole E, Maes B, 50. Ambuhl P, Olsson A G, Staffler B, Pedersen T R. Risk factors for reaching renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial. TRANSPLANTATION, 79: 205-212 (2005) Lutz J, Yao Y S, Song E W, Antus B, Hamar P, Liu S Y, Heemann U. Inhibition of matrix metalloproteinases during * 5 chronic allograft nephropathy in rats. TRANSPLANTATION, 79: 655-661 (2005) Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani G L, Sainz M, 5 Bresadola F, Mioni G. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. TRANSPLANT PROC, 37: 991-993 (2005) Reis K, Arinsoy T, Derici U, Gonen S, Bicik Z, Soylemezoglu O, Yasavul U, Hasanoglu E, Sindel S. Angiotensinogen 53. and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. CLIN TRANSPLANT, 19: 10-14 (2005) Berthier C C, Lods N, Joosten S A, van Kooten C, Leppert D, Lindberg R L P, Kappeler A, Raulf F, Sterchi E E, Lottaz 5 D, Marti H P. Differential regulation of metzincins in experimental chronic renal allograft rejection: Potential markers and novel therapeutic targets. KIDNEY INT, 69: 358-368 (2006) Ersoy A. Current and future antihypertensive drugs in post-transplant hypertension and related patents. EXPERT OPIN 55. THER PAT, 16: (8) 1093-1106 (2006) Lutz J, Risch K, Liu S, Antus B, Schmaderer C, Roos M, Ouyang N, Lehmann M, Heemann U. Angiotensin type 1 and * 56. type 2 receptor blockade in chronic allograft nephropathy. KIDNEY INT, 70: (6) 1080-1088 (2006) Ishizaka N, Matsuzaki G, Saito K, Noiri E, Mori I, Nagai R. Expression and localization of PDGF-B, PDGF-D, and 57. PDGF receptor in the kidney of angiotensin II-infused rat. LABORATORY INVESTIGATION 86 (12): 1285-1292 (2006) 48. Szabo A, Tulassay T, Melegh B, Szabo T, Vannay A, Fekete A, Süveges Zs, Reusz GS. Hyperhomocysteinemia and MTHFR C677T gene polymorphism in renal transplant patients. Arch Dis Child 2001; 85: 47-49 IF:2,129 Független idézettség: 8 Ueland P M, Monsen A L B. Total homocysteine is making its way into pediatric laboratory diagnostics Commentary. EUR J CLIN INVEST, 31: 928-930 (2001) Aldamiz Echevarria L, Sanjurjo P, Vallo A, Aquino L, Perez Nanclares G, Gimeno P, Rueda M, Ruiz J I, Urreizti R, Rodriguez Soriano J. Hyperhomocysteinemia in children with renal transplants. PEDIAT NEPHROL, 17: 718-723 (2002) Filler G, Hocher B. The emerging role of gene polymorphisms determining outcome after solid-organ transplantation. 3. PEDIATR TRANSPLANT, 6: 12-14 (2002) Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, Massy Z A, Ben Maiz H, Lacour B, Mebazaa A. Hyperhomocysteinemia and end-stage renal disease: Determinants and association with cardiovascular disease in Tunisian patients. CLIN CHEM LAB MED, 41: 675-680 (2003) Monsen A L B, Ueland P M. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to 5. adolescence. AMER J CLIN NUTR, 78: 7-21 (2003) Tory K, Suveges Z, Horvaath E, Bokor E, Sallay P, Berta K, Szabo A, Tulassay T, Reusz G S. Autonomic dysfunction in * 6. uremia assessed by heart rate variability. PEDIAT NEPHROL, 18: 1167-1171 (2003) Ueland P M, Monsen A L B. Hyperhomocysteinemia and B-vitamin deficiencies in infants and children. CLIN CHEM 7. LAB MED, 41: 1418-1426 (2003) Belson A, Sanchez J, Alexander S R, Salvatierra O, Dar M H, Reif S, Yorgin P D. Hyperhomocysteinemia in pediatric 8. and young adult renal transplant recipients. PEDIATR TRANSPLANT, 8: 161-166 (2004) Viklicky O, Hubacek J A, Kvasnicka J, Matl I, Voska L, Skibova J, Teplan V, Vitko S. Association of 9. methylenetetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy. CLIN BIOCHEM, 37: 919-924 (2004) 49. Viklicky O, Hubacek JA, Vitko S, Heemann UW, Vasarhelyi B, Lacha J, Kohnle M, Szabo A. G- protein β3-subunit and enos gene polymorphism and long-term renal graft function. Kidney Blood Press R 2002; 25(4): 245-249I IF: 0.968 Független idézettség: 2 Cobo M, Barrios Y, Inigo P, Bigo C, Alvarez A, Martin B, Campistol J M, Hernandez D, Salido E, Torres A. Analyses of genetic risk factors associated to chronic nephropathy of renal transplant: genetic polimorphisms of cytokynes, adhesion molecules, platelet-coagulation system and cardiovascular risk markers. NEFROLOGIA, 24: 49-56 (2004) Khan F, Agrawal S, Agrawal S. Genetic predisposition and renal allograft failure - Implication of non-hla genetic variants. MOLECULAR DIAGNOSIS & THERAPY 10 (4): 205-219 2006

50. Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. Kidney Int 2002; 62 (4): 1364-1371 IF: 5,016 Független idézettség: 11 Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo A J. Sex differences in the * alterations of Na+,K+-ATPase following ischaemia-reperfusion injury in the rat kidney. J PHYSIOL-LONDON, 555: 471-480 (2004) Muller V, Szabo A. Gender associated differences in the progression of renal diseases. LEGE ARTIS MEDICINAE, 14: * (1) 26-31 (2004) Park K M, Kim J I, Ahn Y, Bonventre A J, Bonventre J V. Testosterone is responsible for enhanced susceptibility of 3. males to ischemic renal injury. J BIOL CHEM, 279: 52282-52292 (2004) Shibata Y, Takaoka M, Maekawa D, Kuwahara C, Matsumura Y. Involvement of nitric oxide in the suppressive effect of 17 beta-estradiol on endothelin-1 overproduction in ischemic acute renal failure. J CARDIOVASC PHARMACOL, 44: S459-S461 (2004) Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal * 5. vascular endothelial growth factor mrna expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL, 89: 435-444 (2004) Vannay A, Fekete A, Muller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo A J. Effects of histamine and * 6. the H2 receptor antagonist ranitidine on ischemia-induced acute renal failure: Involvement of IL-6 and vascular endothelial growth factor. KIDNEY BLOOD PRESSURE RES, 27: 105-113 (2004) Gu Y L, Dirsch O, Dahmen U, Ji Y, He Q, Chi H D, Broelsch C E. Impact of donor gender on male rat recipients of 7. small-for-size liver grafts. LIVER TRANSPLANT, 11: 669-678 (2005) Kher A, Meldrum K K, Wang M J, Tsai B M, Pitcher J A, Meldrum D R. Cellular and molecular mechanisms of sex 8. differences in renal ischemia-reperfusion injury. CARDIOVASC RES, 67: 594-603 (2005) Park K M, Cho H J, Bonventre J V. Orchiectomy reduces susceptibility to renal ischemic injury: a role for heat shock 9. proteins. BIOCHEM BIOPHYS RES COMMUN, 328: 312-317 (2005) Reckelhoff J F, Yanes L L, Iliescu R, Fortepiani L A, Granger J P. Testosterone supplementation in aging men and 10. women: possible impact on cardiovascular-renal disease. AMER J PHYSIOL-RENAL PHYSIOL, 289: F941-F948 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The * 1 role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) Sudo T, Ishii A, Asami J, Uematsu Y, Saitoh M, Nakamura A, Tada N, Ohnuki T, Komurasaki T, Nakagawa J. 1 Transgenic mice over-expressing dicarbonyl/l-xylulose reductase gene crossed with KK-A(y) diabetic model mice: An animal model for the metabolism of renal carbonyl compounds. EXP ANIM, 54: 385-394 (2005) Wei Q Q, Wang M H, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. AMER J 13. NEPHROL, 25: 491-499 (2005) Choudhry M A, Bland K I, Chaudry I H. Gender and susceptibility to sepsis following trauma. ENDOCR METAB 1 IMMUN DISORD DRUG TARG, 6: (2) 127-135 (2006) Kim J, In S K, Young M S, Eun S Y, Dae K K, Dong G L, Park J -W, Bonventre J V, Kwon M P. Orchiectomy attenuates 15. post-ischemic oxidative stress and ischemia/reperfusion injury in mice: A role for manganese superoxide dismutase. J BIOL CHEM, 281: (29) 20349-20356 (2006) 16. Metcalfe P D, Meldrum K K. Sex differences and the role of sex steroids in renal injury. J UROL, 176: 15-21 (2006) Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock * 17. protein 72 expression and localization in rats following renal ischemia-reperfusion injury. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 291 (4): F806-F811 (2006) 5 Szabó Attila, Müller Veronika. A transzplantált vese hosszú távú működését befolyásoló faktorok. Orvosi Hetilap 2002, 143(51): 2811-2819 Független idézettség: 2 Yang Y L, Li J P, Dou K F, Li K Z. Influence of liver nonparenchymal cell infusion combined with Cyclosporin A on rejection of rat small bowel transplantation. WORLD J GASTROENTERO, 9: (12) 2859-2862 (2003) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. Hypertonia és Nephrologia, 9 (3-4): 150-156 (2005) 5 Szabo AJ, L Wagner A Erdely K, Lau C, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003, 64(5): 1765-1771 IF: 5,302 Független idézettség: 1

Erdely A, Freshour G, Smith C, Engels K, Olson J L, Baylis C. Protection against puromycin aminonucleoside-induced * chronic renal disease in the Wistar-Furth rat. AMER J PHYSIOL-RENAL PHYSIOL, 287: F81-F89 (2004) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) Baylis C. Acute and long-term effects of modified hemoglobin (HBOC-201) in a rat model of hypertension and chronic * 3. kidney disease. TRANSFUSION, 46: 1104-1111 (2006) Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. NAT CLIN PRACT * NEPHROL, 2: 209-220 (2006) * 5. Baylis C. Nitric oxide deficiency in chronic renal disease. EUR J CLIN PHARMACOL, 62: 123-130 (2006) Erdely A, Freshour G, Baylis C. Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar- * 6. Furth rat. AMER J PHYSIOL-REGUL INTEGR C, 290: R66-R72 (2006) Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of long-term protective effect of * 7. antioxidant/anti-inflammatory therapy in transplant-induced ischemia/reperfusion injury. AMERICAN JOURNAL OF NEPHROLOGY 26 (3): 213-217 2006 53. Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo AJ. Sex differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. J Physiol (London.) 2004; 555(2): 471-80 IF: 4,346 Független idézettség: 9 Narkar V, Kunduzoa O, Hussain T, Cambon C, Parini A, Lokhandwala M. Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. KIDNEY INT, 66: (2) 633-640 (2004) Caron A, Desrosiers R R, Beliveau R. Ischemia injury alters endothelial cell properties of kidney cortex: Stimulation of MMP-9. EXP CELL RES, 310: 105-116 (2005) 3. Kher A, Meldrum K K, Wang M J, Tsai B M, Pitcher J A, Meldrum D R. Cellular and molecular mechanisms of sex differences in renal ischemia-reperfusion injury. CARDIOVASC RES, 67: 594-603 (2005) Schlattjan J H, Biggemann F, Greven J. Gender differences in renal tubular taurocholate transport. NAUNYN- SCHMIED ARCH PHARMACOL, 371: 449-456 (2005) 5. Wei Q Q, Wang M H, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. AMER J NEPHROL, 25: 491-499 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The *6. role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) 7. Du X J, Fang L, Kiriazis H. Sex dimorphism in cardiac pathophysiology: Experimental findings, hormonal mechanisms, and molecular mechanisms. PHARMACOL THER, 111: 434-475 (2006) 8. Metcalfe P D, Meldrum K K. Sex differences and the role of sex steroids in renal injury. J UROL, 176: 15-21 (2006) 9. Molinas S M, Trumper L, Serra E, Elias M M. Evolution of renal function and Na+, K+-ATPase expression during ischaemia-reperfusion injury in rat kidney. MOL CELL BIOCHEM, 287: 33-42 (2006) Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock *10. protein 72 expression and localization in rats following renal ischemia-reperfusion injury. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 291 (4): F806-F811 OCT 2006 1 Bagshaw SM, Mortis G, Godinez-Luna T, Doig CJ, Laupland KB. Renal recovery after severe acute renal failure. Int J Artif Organs. 2006 Nov;29(11):1023-30 5 Müller V, Szabó A. Nemi különbségek a vesebetegségek progressziójában. Lege Artis Medicinae 2004; 14(1): 26-31 Független idézettség: 1 Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) 55. Vannay A, Fekete A, Müller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo AJ. The effects of histamine and the H2 receptor antagonist ranitidine on ischemia induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. Kidney Blood Press R 2004; 27: 105-113 IF: 1,067 Független idézettség: 2 * Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal vascular endothelial growth factor mrna expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL,

89: 435-444 (2004) Bates C M, Lin F M. Future strategies in the treatment of acute renal failure: growth factors, stem cells, and other novel therapies. CURR OPIN PEDIATR, 17: 215-220 (2005) Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, Viklicky O. Regulators of angiogenesis * 3. in renal ischemia/reperfusion injury in normotensive and hypertensive rats: Effect of tacrolimus. TRANSPLANT PROC, 37: 352-354 (2005) Xie H, He S-H. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. WORLD J GASTROENTERO, 11: (19) 2851-2857 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The *5. role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) 56. Fekete A, Viklicky O, Hubácek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between Heat Shock Protein (HSP) 70s and Toll like Receptor Polymorphisms with Long-Term Renal Allograft Survival. Transplant Int 2006; 19: 190 196 IF: 1,797 57. Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock protein 72 expression and localization in rats following renal ischaemia-reperfusion injury. Am J Physiol Renal Physiol. 2006; 291(4): F806-F811 IF: 4,263 Független idézettség: 1 Bagshaw SM, Mortis G, Godinez-Luna T, Doig CJ, Laupland KB. Renal recovery after severe acute renal failure. Int J Artif Organs. 2006 Nov;29(11):1023-30 Össz IF: 29,259 Független idézettség: 85 A disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények 58. Heemann U, Szabo A, Hamar P, Müller V, Witzke O, Philipp Th. LPS pretreatment protects from renal ischemia/reperfusion injury. Possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156: 287-293 IF: 6,971 Független idézettség: 31 Daemen M A R C, Heemskerk V H, van t Veer C, Denecker G, Wolfs T G A M, Vandenabeele P, Buurman W A. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. CIRCULATION, 102: 1420-1426 (2000) Rayhane N, Fitting C, Lortholary O, Dromer F, Cavaillon J M. Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. INFEC IMMUNITY, 68: 3748-3753 (2000) Rumbeiha W K, Fitzgerald S D, Braselton W E, Roth R A, Pestka J J, Kaneene J B. Augmentation of mercury-induced 3. nephrotoxicity by endotoxin in the mouse. TOXICOLOGY, 151: 103-116 (2000) Ackermann M, Reuter M, Flohe S, Bahrami S, Redl H, Schade F U. Cytokine synthesis in the liver of endotoxin-tolerant and normal rats during hemorrhagic shock. J ENDOTOXIN RES, 7: 105-112 (2001) Colletti L M, Green M. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous 5. lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro. SHOCK, 16: 312-319 (2001) Ganey P E, Roth R A. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. 6. TOXICOLOGY, 169: 195-208 (2001) Zimmermann C, Ginis I, Furuya K, Klimanis D, Ruetzler C, Spatz M, Hallenbeck J M. Lipopolysaccharide-induced 7. ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. BRAIN RES, 895: 59-65 (2001) 8. Bonventre J V. Kidney ischemic preconditioning. CURR OPIN NEPHROL HYPERTENS, 11: 43-48 (2002) Chatterjee P K, Zacharowski K, Cuzzocrea S, Brown P A J, Stewart K N, Mota Filipe H, Thiemermann C. Lipoteichoic 9. acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. KIDNEY INT, 62: 1249-1263 (2002) Fernandez D E, Siemers F, Flohe S, Nau M, Schade F U. Effects of endotoxin tolerance on liver function after hepatic 10. ischemia/reperfusion injury in the rat. CRIT CARE MED, 30: (1) 165-170 (2002) * 1 Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal

ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Okada M, Yan S F, Pinsky D J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses 1 ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J, 16: 1861-1868 (2002) Shimizu M, Tamamori Adachi M, Arai H, Tabuchi N, Tanaka H, Sunamori M. Lipopolysaccharide pretreatment 13. attenuates myocardial infarct size: A possible mechanism involving heat shock protein 70-inhibitory kappa B alpha complex and attenuation of nuclear factor kappa B. J THORAC CARDIOVASC SURG, 124: 933-941 (2002) Tremblay J, Chen H F, Peng J Z, Kunes J, Vu M D, Sarkissian S D, Deblois D, Bolton A E, Gaboury L, Marshansky V, 1 Gouadon E, Hamet P. Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. TRANSPLANTATION, 74: 1425-1433 (2002) Wenzel U O, Wolf G, Jacob I, Thaiss F, Helmchen U, Stahl R A K. Chronic anti-thy-1 nephritis is aggravated in the 15. nonclipped but not in the clipped kidney of Goldblatt hypertensive rats. KIDNEY INT, 61: 2119-2131 (2002) Wenzel U O, Thaiss F, Helmchen U, Stahl R A K, Wolf G. Angiotensin II infusion ameliorates the early phase of a 16. mesangioproliferative glomerulonephritis. KIDNEY INT, 61: 1020-1029 (2002) Aragno M, Cutrin J C, Mastrocola R, Perrelli M G, Restivo F, Poli G, Danni O, Boccuzzi G. Oxidative stress and kidney 17. dysfunction due to ischemia/reperfusion in rat: Attenuation by dehydroepiandrosterone. KIDNEY INT, 64: 836-843 (2003) Cavaillon J M, Adrie C, Fitting C, Adib Conquy M. Endotoxin tolerance: is there a clinical relevance? J ENDOTOXIN 18. RES, 9: 101-107 (2003) Dirnagl U, Simon R P, Hallenbeck J M. Ischemic tolerance and endogenous neuroprotection. TRENDS NEUROSCI, 26: 19. 248-254 (2003) Friedrich I, Spillner J, Lu E X, Barnscheidt M, Kuss O, Sablotzki A, Schade F U, Borgermann J. Induction of endotoxin 20. tolerance improves lung function after warm ischemia in dogs. AMER J PHYSIOL-LUNG CELL M PH, 284: L224-L231 (2003) Hiki N, Mimura Y, Hatao F, Kojima J, Ogawa T, Tsuji E, Kaminishi M. Sublethal endotoxin administration evokes superresistance to systemic hypoxia in rats. J TRAUMA, 54: 584-589 (2003) 2 Obermaier R, Drognitz O, Grub A, von Dobschuetz E, Schareck W, Hopt U T, Benz S. Endotoxin preconditioning in 2 pancreatic ischemia/reperfusion injury. PANCREAS, 27: E51-E56 (2003) Vaidya V S, Shankar K, Lock E A, Dixon D, Mehendale H M. Molecular mechanisms of renal tissue repair in survival 23. from acute renal tubule necrosis: Role of ERK1/2 pathway. TOXICOL PATHOL, 31: 604-618 (2003) Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo A J. Sex differences in the * 2 alterations of Na+,K+-ATPase following ischaemia-reperfusion injury in the rat kidney. J PHYSIOL-LONDON, 555: 471-480 (2004) Kariko K, Weissman D, Welsh F A. Inhibition of toll-like receptor and cytokine signaling - A unifying theme in ischemic 25. tolerance. J CEREBR BLOOD FLOW METABOL, 24: 1288-1304 (2004) Kim S H, Lee S M. Expression of hepatic vascular stress genes following ischemia/reperfusion and subsequent 26. endotoxemia. ARCH PHARM RESEARCH, 27: 769-775 (2004) Obermaier R, von Dobschuetz E, Muhs O, Keck T, Drognitz O, Jonas L, Schareck W, Hopt U T, Benz S. Influence of 27. nitric oxide on microcirculation in pancreatic ischemia/reperfusion injury: an intravital microscopic study. TRANSPLANT INT, 17: 208-214 (2004) Vannay A, Fekete A, Muller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo A J. Effects of histamine and * 28. the H2 receptor antagonist ranitidine on ischemia-induced acute renal failure: Involvement of IL-6 and vascular endothelial growth factor. KIDNEY BLOOD PRESSURE RES, 27: 105-113 (2004) Day Y J, Huang L, Ye H, Linden J, Okusa M D. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated 29. tissue protection: role of macrophages. AMER J PHYSIOL-RENAL PHYSIOL, 288: F722-F731 (2005) Patel N S A, Chatterjee P K, Di Paola R, Mazzon E, Britti D, de Sarro A, Cuzzocrea S, Thiemermann C. Endogenous 30. interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J PHARMACOL EXP THER, 312: 1170-1178 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The 3 role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) Godet C, Goujon J M, Petit I, Lecron J C, Hauet T, Mauco G, Carretier M, Robert R. Endotoxin tolerance enhances 3 interleukin-10 renal expression and decreases ischemia-reperfusion renal injury in rats. SHOCK, 25: 384-388 (2006) Lastres Becker I, Cartmell T, Molina Holgado F. Endotoxin preconditioning protects neurones from in vitro ischemia: 33. Role of endogenous IL-1 beta and TNF-alpha. J NEUROIMMUNOL, 173: 108-116 (2006) Ishiyama K, Ohdan H, Tokita D, Shishida M, Tanaka Y, Irei T, Asahara T. Induction of endotoxin tolerance inhibits 3 alloimmune responses. TRANSPLANT IMMUNOLOGY 16 (3-4): 158-165 (2006) 59. Viklicky O, Zou H, Müller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502 IF: 4,035 Független idézettség: 37 * Vikclicky O, Matl I, Lacha J, Muller V, Szabo A, Heemann U W. Chronic renal allograft rejection: Part II. Possibilities of therapy. CASOPIS LEKARU CESKYCH, 139: (17) 524-528 (2000)

Dumont F J. Everolimus Novartis. CURR OPINION INVEST DRUGS, 2: (9) 1220-1234 (2001) Gaschen L, Audet M, Menninger K, Schuurman H J. Ultrasonographic findings of functioning renal allografts in the 3. cynomolgus monkey (Macaca fascicularis). J MED PRIMATOL, 30: 46-55 (2001) Gregory C R, Katznelson S, Griffey S M, Kyles A E, Berryman E R. Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts. TRANSPLANTATION, 72: 989-993 (2001) Klupp J, Langrehr J M, Junge G, Neuhaus P. Inhibitors of mammalian target of rapamycin. DRUG FUTURE, 26: 5. 1179-1189 (2001) Nashan B. The role of Certican (Everolimus, Rad) in the many pathways of chronic rejection. TRANSPLANT PROC, 6. 33: 3215-3220 (2001) 7. Neuhaus P, Klupp J, Langrehr J M. mtor inhibitors: An overview. LIVER TRANSPLANT, 7: 473-484 (2001) 8. Pohanka E. New immunosuppressive drugs: An update. CURR OPIN UROLOGY, 11: (2) 143-151 (2001) Vicklicky O, Matl I. Rapamycin: The new immunosuppressant efficient to inhibit the chronic rejection? CASOPSIS * 9. LEKARU CESKYCH, 140: (1) 22-25 (2001) Laplante A, Demeule M, Murphy G F, Beliveau R. Interaction of immunosuppressive agents rapamycin and its 10. analogue SDZ-RAD with endothelial P-GP. TRANSPLANT PROC, 34: 3393-3395 (2002) 1 Nashan B. Review of the proliferation inhibitor everolimus. EXPERT OPIN INVESTIG DRUGS, 11: 1845-1857 (2002) 1 Nashan B. Early clinical experience with a novel rapamycin derivative. THER DRUG MONIT, 24: 53-58 (2002) 13. Paul L. New insights in chronic allograft rejection. CURR OPIN UROL, 12: (2) 89-93 (2002) Riederer I, Silva Barbosa S D, Rodrigues M L, Savino W. Local antilaminin antibody treatment alters the rejection 1 pattern of murine cardiac allografts: Correlation between cellular infiltration and extracellular matrix. TRANSPLANTATION, 74: 1515-1522 (2002) Salm P, Taylor P J, Lynch S V, Pillans P I. Quantification and stability of everolimus (SDZ RAD) in human blood by 15. high-performance liquid chromatography-electrospray tandem mass spectrometry. J CHROMATOGR B, 772: 283-290 (2002) Scholten E M, de Fijter J W, Paul L C. Pharmacotherapeutic approach to prevent or treat chronic allograft. Curr Drug 16. Targets - Cardiovascular and Haematological Disorders, 2: (2) 79-96 (2002) Beckmann N, Cannet C, Fringeli Tanner M, Baumann D, Pally C, Bruns C, Zerwes H G, Andriambeloson E, Bigaud M 17. Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. MAGN RESON MED, 49: 459-467 (2003) Belperio J A, Lake K, Tazelaar H, Keane M P, Strieter R M, Lynch J P. Bronchiolitis obliterans syndrome complicating 18. lung or heart-lung transplantation. SEMIN RESPIR CRIT CARE MED, 24: 499-530 (2003) Cahill B C, Somerville K T, Crompton J A, Parker S T, O Rourke M K, Stringham J C, Karwande S V. Early experience 19. with sirolimus in lung transplant recipients with chronic allograft rejection. J HEART LUNG TRANSPLANT, 22: 169-176 (2003) Jolicoeur E M, Qi S J, Xu D S, Dumont L, Daloze P, Chen H F. Combination therapy of mycophenolate mofetil and 20. rapamycin in prevention of chronic renal allograft rejection in the rat. TRANSPLANTATION, 75: 54-59 (2003) Lutz J, Zou H Q, Liu S Y, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with * 2 everolimus. TRANSPLANTATION, 76: 508-515 (2003) Matsumoto Y, Hof A, Baumlin Y, Hof R P. Differential effect of cyclosporine A and SDZ RAD on neointima formation of 2 carotid allografts in apolipoprotein E-deficient mice. TRANSPLANTATION, 76: 1166-1170 (2003) Pan F, Ebbs A, Wynn C, Erickson L, Jang M S, Crews G, Fisniku O, Kobayashi M, Paul L C, Benediktsson H, Jiang H 23. S. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. TRANSPLANTATION, 75: 1110-1114 (2003) 2 Augustine J J, Hricik D E. Experience with everolimus. TRANSPLANT PROC, 36: 500S-503S (2004) 25. Chapman T M, Perry C M. Everolimus. DRUGS, 64: 861-872 (2004) Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary 26. excretion of bile salts and cholesterol in rats. DIGEST DIS SCI, 49: 30-37 (2004) Formica R N, Lorber K M, Friedman A L, Bia M J, Lakkis F, Smith J D, Lorber M I. The evolving experience using 27. everolimus in clinical transplantation. TRANSPLANT PROC, 36: 495S-499S (2004) Holmes M, Chilcott J, Walters S, Whitby S, Akehurst R. Economic evaluation of everolimus versus mycophenolate 28. mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. TRANSPLANT INT, 17: 182-187 (2004) 29. Pascual J. Everolimus: immunosuppression with antilymphoproliferative therapy. NEFROLOGIA, 24: 112-123 (2004) Starling R C, Hare J M, Hauptman P, Mccurry K R, Mayer H W, Kovarik J M, Schmidli H. Therapeutic drug 30. monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. AM J TRANSPLANT, 4: 2126-2131 (2004) Viklicky O, Bohmova R, Ouyang N, Honsova E, Lodererova A, Mandys V, Vitko S, Lutz J, Heemann U W. Effect of * 3 sirolimus on renal ischaemia/reperfusion injury in normotensive and hypertensive rats. TRANSPLANT INT, 17: 432-441 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft * 3 nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004) Wu M J, Shu K H, Cheng C H, Chen C H. Sirolimus in chronic allograft nephropathy. TRANSPLANT PROC, 36: 2053-33. 2055 (2004)

Baldelli S, Murgia S, Merlini S, Zenoni S, Perico N, Remuzzi G, Cattaneo D. High-performance liquid chromatography 3 with ultraviolet detection for therapeutic drug monitoring of everolimus. J CHROMATOGR B, 816: 99-105 (2005) Lorber M I, Ponticelli C, Whelchel J, Mayer H W, Kovarik J, Li Y L, Schmidli H. Therapeutic drug monitoring for 35. everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. CLIN TRANSPLANT, 19: 145-152 (2005) Neumayer H H. Introducing everolimus (Certican) in organ transplantation: An overview of preclinical and early 36. clinical developments. TRANSPLANTATION, 79: S72-S75 (2005) Andres V, Castro C, Campistol J M. Potential role of proliferation signal inhibitors on atherosclerosis in renal 37. transplant patients. NEPHROL DIALYSIS TRANSPLANT, 21: (2006) Bloudickova S, Rajnoch J, Lodererova A, Honsova E, Viklicky O. Mycophenolate mofetil ameliorates accelerated * 38. progressive nephropathy in rat. KIDNEY BLOOD PRESSURE RES, 29: 60-66 (2006) Bocchi E A, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, 39. Perrone S V. Recommendations for use of everolimus after heart transplantation: Results from a Latin-American Consensus Meeting. TRANSPLANT PROC, 38: 937-942 (2006) Dunn C, Croom K F. Everolimus - A review of its use in renal and cardiac transplantation. DRUGS, 66: 547-570 40. (2006) Pascual J, Boletis I N, Campistol J M. Everolismus (Certican) in renal transplantation: a review of clinical trial data, 4 current usage and fuure directions. TRANSPLANTATION REVIEWS, 20: (1) 1-18 (2006) Webster A C, Lee V W S, Chapman J R, Craig J C. Target of rapamycin inhibitors (Sirolimus and Everolimus) for 4 primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. TRANSPLANTATION, 81: 1234-1248 (2006) Serr F, Lauer H, Armann B, Ludwig S, Thiery J, Fiedler M, Ceglarek U, Tannapfel A, Uhlmann D, Hauss J, 43. Witzigmann H. Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemiareperfusion injury. AMERICAN JOURNAL OF TRANSPLANTATION 7 (1): 48-56 (2007) 60. Hamar P, Liu S, Viklicky O, Szabo A, Müller V, Heemann U. Cyclosporine A and Azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69: 1290-1295 IF: 4,035 Független idézettség: 3 *3. Noris M, Azzollini N, Pezzotta A, Mister M, Benigni A, Marchetti G, Gagliardini E, Perico N, Remuzzi G. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J AMER SOC NEPHROL, 12: 1937-1946 (2001) Afzali B, Taylor A L, Goldsmith D J A. What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations. KIDNEY INT, 68: 2429-2443 (2005) Hamar P, Liptak P, Heemann U, Ivanyi B. Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft nephropathy. TRANSPLANT INT, 18: 863-870 (2005) Zheng L, Orsida B, Whitford H, Levvey B, Ward C, Walters E H, Williams T J, Snell G I. Longitudinal comparisons of lymphocytes and subtypes between airway wall and bronchoalveolar lavage after human lung transplantation. TRANSPLANTATION, 80: 185-192 (2005) 6 Losonczy G, Kriston T, Szabo A, Müller V, Harvey J, Hamar P, Heemann U, Baylis C. Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res 2000; 47: 183-191 IF: 3,783 Független idézettség: 18 Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? PHARMACOL THER, 91: 179-213 (2001) Morin M J, Karr S M, Faris R A, Gruppuso P A. Developmental variability in expression and regulation of inducible nitric oxide synthase in rat intestine. AMER J PHYSIOL-GASTROINTEST L, 281: G552-G559 (2001) * 3. Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Okawa T, Vedernokov Y P, Saade G R, Garfield R E. Gender differences in contractile and relaxing responses of aortic rings from lipopolysaccharide-treated rats. GYNECOL ENDOCRINOL, 16: 225-233 (2002) 5. Beery T A. Sex differences in infection and sepsis. Crit Care Nursing Clinics North America, 15: (1) 55-62 (2003) Bindl L, Buderus S, Dahlem P, Demirakca S, Goldner M, Huth R, Kohl M, Krause M, Kuhl P, Lasch P, Lewandowski 6. K, Merz U, Moeller J, Mohamad Y, Peters M, Porz W, Vierzig A, Ruchard J, Scharf J, Varnholt V. Gender-based differences in children with sepsis and ARDS: The ESPNIC ARDS database group. INTENS CARE MED, 29: 1770-1773 (2003) Helmer K S, Cui Y, Chang L, Dewan A, Mercer D W. Effects of ketamine/xylazine on expression of tumor necrosis 7. factor-alpha, inducible nitric oxide synthase, and cyclo-oxygenase-2 in rat gastric mucosa during endotoxemia. SHOCK, 20: 63-69 (2003) 8. Kuebler J F, Yokoyama Y, Jarrar D, Toth B, Rue L W, Bland K I, Wang P, Chaudry I H. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. ARCH SURG, 138: 727-734 (2003)

de la Fuente M, Baeza I, Guayerbas N, Puerto M, Castillo C, Salazar V, Ariznavarreta C, F Tresguerres J A. Changes 9. with ageing in several leukocyte functions of male and female rats. BIOGERONTOLOGY, 5: 389-400 (2004) Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal * 10. vascular endothelial growth factor mrna expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL, 89: 435-444 (2004) Finamore A, Devirgiliis C, Panno D, D Aquino M, Polito A, Venneria E, Raguzzini A, Coudray C, Mengheri E. 1 Immune response in relation to zinc status, sex and antioxidant defence in Italian elderly population: the ZENITH study. EUR J CLIN NUTR, 59: S68-S72 (2005) Gautier Sauvigne S, Colas D, Parmantier P, Clement P, Gharib A, Sarda N, Cespuglio R. Nitric oxide and steep. 1 SLEEP MED REV, 9: 101-113 (2005) Imahara S D, Jelacic S, Junker C E, O Keefe G E. The influence of gender on human innate immunity. SURGERY, 13. 138: 275-282 (2005) Inaba K, Suzuki S, Ihara H, Sakaguchi T, Baba S, Urano T, Konno H, Nakamura S. Sexual dimorphism in endotoxin 1 susceptibility after partial hepatectomy in rats. J HEPATOL, 42: 719-727 (2005) Pitcher J M, Wang M J, Tsai B M, Kher A, Turrentine M W, Brown J W, Meldrum D R. Preconditioning: Gender 15. effects. J SURG RES, 129: 202-220 (2005) Pitcher J M, Nagy R D, Tsai B M, Wang M J, Kher A, Meldrum D R. Is the preconditioning threshold different in 16. females? J SURG RES, 125: 168-172 (2005) Xu J, Liu L M. The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic 17. shock in the rat. SHOCK, 23: 576-581 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The 18. role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150-156 (2005) Lipcsey M, Larsson A, Eriksson M B, Sjolin J. Inflammatory, coagulatory and circulatory responses to logarithmic 19. increases in the endotoxin dose in the anaesthetised pig. J ENDOTOXIN RES, 12: 99-112 (2006) Nelson N T, Mahomed A J, Pitcher J M, Tsai B M, Wang M J, Mahomed Y, Brown J W, Crisostomo P, Meldrum D R. 20. Does endogenous testosterone mediate the lower preconditioning threshold in males?. J SURG RES, 131: 86-90 (2006) 6 Reusz GS Szabo A, Ferenc P, Kenesei É, Sallay P, Latta K, Szabó A, Szabó A. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000; 83: 146-151 IF: 1,866 Független idézettség: 19 Alon U S. Preservation of bone mass in pediatric dialysis and transplant patients. ADV RENAL REPLACE THER, 8: 191-205 (2001) Behnke B, Kemper M J, Kruse H P, Muller Wiefel D E. Bone mineral density in children with primary hyperoxaluria type I. NEPHROL DIALYSIS TRANSPLANT, 16: 2236-2239 (2001) Kovarik J. Transplantation bone disease: Bone metabolism after kidney transplantation 3. [Transplantationsosteopathie: Knochenstoffwechsel nach nierentransplantation]. JOURNAL FUR MINERALSTOFFWECHSEL, 8: (1) 29-33 (2001) Saland J M, Goode M L, Haas D L, Romano T A, Seikaly M G. The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. AM J TRANSPLANT, 1: 243-250 (2001) 5. Lutz J, Heemann U. Postoperative care for renal transplant recipients. INTERNIST, 43: 1559-1565 (2002) Zlataric D K, Celebic A, Lazic B, Baucic I, Komar D, Stipetic Ovcaricek J, Ibrahimagic L. Influence of age and 6. gender on radiomorphometric indices of the mandible in removable denture wearers. COLLEGIUM ANTROPOL, 26: 259-266 (2002) 7. Daniels M W, Wilson D M, Paguntalan H G, Hoffman A R, Bachrach L K. Bone mineral density in pediatric transplant recipients. TRANSPLANTATION, 76: 673-678 (2003) 8. Zimakas P J A, Sharma A K, Rodd C J. Osteopenia and fractures in cystinotic children post renal transplantation. PEDIAT NEPHROL, 18: 384-390 (2003) El Husseini A A, El Agroudy A E, El Sayed M, Sobh M A, Ghoneim M A. A prospective randomized study for the 9. treatment of bone loss with vitamin D during kidney transplantation in children and adolescents. AM J TRANSPLANT, 4: 2052-2057 (2004) Ruth E M, Weber L T, Schoenau E, Wunsch R, Seibel M J, Feneberg R, Mehls O, Tonshoff B. Analysis of the 10. functional muscle-bone unit of the forearm in pediatric renal transplant recipients. KIDNEY INT, 66: 1694-1706 (2004) 1 Saland J M. Osseous complications of pediatric transplantation. PEDIATR TRANSPLANT, 8: 400-415 (2004) 1 Schoenau E, Land C, Stabrey A, Remer T, Kroke A. The bone mass concept: problems in short stature. EUR J ENDOCRINOLOGY, 151: S87-S91 (2004) 13. Schonau E. The peak bone mass concept: is it still relevant? PEDIAT NEPHROL, 19: 825-831 (2004) 1 Sprague S M, Josephson M A. Bone disease after kidney transplantation. SEMIN NEPHROL, 24: 82-90 (2004) 15. Bottcher J, Pfeil A, Rosholm A, Petrovitch A, Seidl B E, Malich A, Schafer M L, Kramer A, Mentzel H J, Lehmann G,